pharma · Systemic Amyloidosis
Jin Lu, MD
Jin Lu, MD is a pharma organization headquartered in CN. Primary therapeutic focus areas include Systemic Amyloidosis. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Bortezomib
Phase 2 · small molecule · Systemic Amyloidosis
Bortezomib for Systemic Amyloidosis is a Phase 2 program (small_molecule) at Jin Lu, MD with 1 ClinicalTrials.gov record(s).
Internal code 2023-358-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jin Lu, MD
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Systemic Amyloidosis
- Status
- active
- Trials
- 1